Cure My Disease

Don't miss your cure!

 Log in / Sign up

Second-Chance stem cell therapy for blood cancer patients

NCT ID NCT07346105

AVAILABLE Disease control Sponsor: Orca Biosystems, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This program gives patients with certain blood cancers access to Orca-T, a donor stem cell therapy, when the commercial version cannot be used. It is for people who have no other treatment options. The program monitors safety but does not test if the therapy works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Orca-T (a donor stem cell therapy for blood cancers)
What this could lead to
If successful, this program could offer a treatment option for patients with blood cancers who have no other approved therapy available.
What could go wrong
This is an expanded access program, not a formal trial, so results are limited. The product is out of specification, which may increase risks like graft failure or severe side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia acute myeloid leukemia hematopoietic and lymphoid system neoplasm mixed phenotype acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOID LEUKEMIA ACUTE MYELOID LEUKEMIA HEMATOLOGIC MALIGNANCIES MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROME

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.